

Antibody against SLE and CLL

PLASMA MEMBRANE STIM1 AS A NEW THERAPEUTIC TARGET FOR SLE AND CLL

AN INNOVATIVE OFFER

Chronic lymphocytic leukemia (CLL) is the leading cause of leukemia in Western countries. To date, no treatment including the novel therapies targeting the B cell receptor (BCR) pathway (e.g. anti-CD20 monoclonal antibodies (mAb), BCR kinase inhibitors), offers a complete remission. It is noteworthy that the rate of treatment interruptions and toxicity remain elevated for these patients.

Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by the presence of autoreactive lymphocytes and of antinuclear auto-antibodies (ANA). It is a multisystemic disease, with heterogenous clinical manifestations. SLE may affect all organs.

The invention relates to the use of the fraction of STIM1 localized to the plasma membrane as a therapeutic target in CLL and SLE by modulating its presence or its activity.

POTENTIAL APPLICATIONS

- **Chronic lymphocytic leukemia**
- **Systemic lupus erythematosus**

INTELLECTUAL PROPERTY

- 1st Patent: EP14290232.9 filed as of 06/08/2014
- 2nd Patent: EP15156694.0 filed as of 26/02/2015

DEVELOPMENT STATUS

- Proof of concept on MRL/Lpr mouse model (SLE)
- New therapeutic pathway
- Proprietary Monoclonal Antibodies

BENEFITS OF THE TECHNOLOGY

- Presence of the marker solely on affected cells
- Expression by the immune cells of the STIM1 protein at the plasma membrane facilitates the accessibility of this target

LABS & SCIENTISTS

- UMR INSERM U1227, LBAI, Brest



CONTACT

SATT OUEST VALORISATION

14 C, Rue du Pâtis Tatelin 35078 RENNES

Tél. +33 (0)2 99 87 56 01 email : info@ouest-valorisation.fr

